Literature DB >> 19144817

Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus.

Anna Söderlund-Strand1, Joyce Carlson, Joakim Dillner.   

Abstract

Human papillomavirus (HPV) infection is a necessary cause of cervical cancer and cervical dysplasia. Accurate and sensitive genotyping of multiple oncogenic HPVs is essential for a multitude of both clinical and research uses. We developed a modified general primer (MGP) PCR system with five forward and five reverse consensus primers. The MGP system was compared to the classical HPV general primer system GP5+/6+ using a proficiency panel with HPV plasmid dilutions as well as cervical samples from 592 women with low-grade cytological abnormalities. The reference method (GP5+/6+) had the desirable high sensitivity (five copies/PCR) for five oncogenic HPV types (HPV type 16 [HPV-16], HPV-18, HPV-56, HPV-59, and HPV-66). The MGP system was able to detect all 14 oncogenic HPV types at five copies/PCR. In the clinical samples, the MGP system detected a significantly higher proportion of women with more than two concomitant HPV infections than did the GP5+/6+ system (102/592 women compared to 42/592 women). MGP detected a significantly greater number of infections with HPV-16, -18, -31, -33, -35, -39, -42, -43, -45, -51, -52, -56, -58, and -70 than did GP5+/6+. In summary, the MGP system primers allow a more sensitive amplification of most of the HPV types that are established as oncogenic and had an improved ability to detect multiple concomitant HPV infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19144817      PMCID: PMC2650955          DOI: 10.1128/JCM.02007-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

1.  Improved amplification of genital human papillomaviruses.

Authors:  P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Bead-based multiplex genotyping of human papillomaviruses.

Authors:  Markus Schmitt; I G Bravo; Peter J F Snijders; Lutz Gissmann; Michael Pawlita; Tim Waterboer
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

3.  The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR.

Authors:  A M de Roda Husman; J M Walboomers; A J van den Brule; C J Meijer; P J Snijders
Journal:  J Gen Virol       Date:  1995-04       Impact factor: 3.891

4.  Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia.

Authors:  N F Schlecht; S Kulaga; J Robitaille; S Ferreira; M Santos; R A Miyamura; E Duarte-Franco; T E Rohan; A Ferenczy; L L Villa; E L Franco
Journal:  JAMA       Date:  2001-12-26       Impact factor: 56.272

5.  Results of the first World Health Organization international collaborative study of detection of human papillomavirus DNA.

Authors:  Wim G V Quint; Sonia R Pagliusi; Nico Lelie; Ethel-Michele de Villiers; Cosette M Wheeler
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

Review 6.  The role of human papillomavirus testing in cervical screening.

Authors:  Kate S Cuschieri; Heather A Cubie
Journal:  J Clin Virol       Date:  2005-03       Impact factor: 3.168

7.  Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study.

Authors:  Susanne K Kjaer; Adriaan J C van den Brule; Gerson Paull; Edith I Svare; Mark E Sherman; Birthe L Thomsen; Mette Suntum; Johannes E Bock; Paul A Poll; Chris J L M Meijer
Journal:  BMJ       Date:  2002-09-14

8.  Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses.

Authors:  B Kleter; L J van Doorn; J ter Schegget; L Schrauwen; K van Krimpen; M Burger; B ter Harmsel; W Quint
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

9.  Typing of human papillomaviruses by consensus polymerase chain reaction and a non-radioactive reverse dot blot hybridization.

Authors:  O Forslund; B G Hansson; B Bjerre
Journal:  J Virol Methods       Date:  1994-09       Impact factor: 2.014

10.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

Authors:  F X Bosch; M M Manos; N Muñoz; M Sherman; A M Jansen; J Peto; M H Schiffman; V Moreno; R Kurman; K V Shah
Journal:  J Natl Cancer Inst       Date:  1995-06-07       Impact factor: 13.506

View more
  50 in total

1.  The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.

Authors:  Carina Eklund; Ola Forslund; Keng-Ling Wallin; Tiequn Zhou; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

2.  Prospective study of human papillomavirus and risk of cervical adenocarcinoma.

Authors:  Lisen Arnheim Dahlström; Nathalie Ylitalo; Karin Sundström; Juni Palmgren; Alexander Ploner; Sandra Eloranta; Carani B Sanjeevi; Sonia Andersson; Thomas Rohan; Joakim Dillner; Hans-Olov Adami; Pär Sparén
Journal:  Int J Cancer       Date:  2010-10-15       Impact factor: 7.396

3.  Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening.

Authors:  A T Hesselink; D A M Heideman; J Berkhof; F Topal; R P Pol; C J L M Meijer; P J F Snijders
Journal:  J Clin Microbiol       Date:  2009-12-30       Impact factor: 5.948

4.  Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix.

Authors:  Karin Sundström; Sandra Eloranta; Pär Sparén; Lisen Arnheim Dahlström; Anthony Gunnell; Anders Lindgren; Juni Palmgren; Alexander Ploner; Carani B Sanjeevi; Mads Melbye; Joakim Dillner; Hans-Olov Adami; Nathalie Ylitalo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-29       Impact factor: 4.254

5.  Comparison of Seegene Anyplex II HPV28 with the PGMY-CHUV assay for human papillomavirus genotyping.

Authors:  C Estrade; R Sahli
Journal:  J Clin Microbiol       Date:  2013-12-11       Impact factor: 5.948

6.  Development of the TypeSeq Assay for Detection of 51 Human Papillomavirus Genotypes by Next-Generation Sequencing.

Authors:  Sarah Wagner; David Roberson; Joseph Boland; Meredith Yeager; Michael Cullen; Lisa Mirabello; S Terence Dunn; Joan Walker; Rosemary Zuna; Mark Schiffman; Nicolas Wentzensen
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

7.  Differing Age-Specific Cervical Cancer Incidence Between Different Types of Human Papillomavirus: Implications for Predicting the Impact of Elimination Programs.

Authors:  Simopekka Vänskä; Tapio Luostarinen; Camilla Lagheden; Carina Eklund; Sara Nordqvist Kleppe; Bengt Andrae; Pär Sparén; Karin Sundström; Matti Lehtinen; Joakim Dillner
Journal:  Am J Epidemiol       Date:  2021-04-06       Impact factor: 4.897

8.  Oral squamous cell carcinoma versus oral verrucous carcinoma: an approach to cellular proliferation and negative relation to human papillomavirus (HPV).

Authors:  José Vieira de Spíndula-Filho; Aparecido Divino da Cruz; Angélica Ferreira Oton-Leite; Aline Carvalho Batista; Cláudio Rodrigues Leles; Rita de Cássia Gonçalves Alencar; Vera Aparecida Saddi; Elismauro Francisco Mendonça
Journal:  Tumour Biol       Date:  2010-12-07

9.  Lack of methylation in the upstream region of human papillomavirus type 6 from aerodigestive tract papillomas.

Authors:  Agustín Enrique Ure; Ola Forslund
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

10.  Prospective study of HPV16 viral load and risk of in situ and invasive squamous cervical cancer.

Authors:  Karin Sundström; Alexander Ploner; Lisen Arnheim Dahlström; Juni Palmgren; Joakim Dillner; Hans-Olov Adami; Nathalie Ylitalo; Pär Sparén
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-11-15       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.